| |
Drug efficiency vs. survival
|
Adjusted drug efficiency vs. survival
|
|---|
|
R2
|
p-value
|
R2
|
p-value
|
|---|
|
Pemetrexed
|
0.36
|
0.40
|
0.84
|
0.09
|
|
Chlorambucil
|
0.14
|
0.37
|
0.42
|
0.08
|
|
Hydroxyurea
|
0.08
|
0.47
|
0.32
|
0.11
|
|
Cisplatin
|
0.46
|
0.14
|
0.67
|
0.05
|
|
Doxorubicin
|
0.05
|
0.55
|
0.25
|
0.17
|
|
Paclitaxel
|
0.24
|
0.18
|
0.40
|
0.07
|
|
Asparaginase
|
0.17
|
0.27
|
0.32
|
0.11
|
|
Etoposide
|
0.00
|
0.95
|
0.14
|
0.32
|
|
Docetaxel
|
0.28
|
0.14
|
0.39
|
0.07
|
|
Vinblastine
|
0.00
|
0.98
|
0.08
|
0.46
|
|
Cytarabine
|
0.08
|
0.47
|
0.15
|
0.30
|
|
Vincristine
|
0.01
|
0.79
|
0.07
|
0.49
|
|
Gemcitabine
|
0.00
|
0.99
|
0.05
|
0.57
|
|
Bleomycin
|
0.37
|
0.08
|
0.41
|
0.06
|
|
Cladribine
|
0.37
|
0.08
|
0.38
|
0.08
|
|
Fludarabine
|
0.01
|
0.85
|
0.01
|
0.81
|
|
Oxaliplatin
|
0.04
|
0.59
|
0.04
|
0.59
|
|
Dacarbazine
|
0.33
|
0.42
|
0.33
|
0.42
|
|
Fluorouracil
|
0.04
|
0.58
|
0.04
|
0.60
|
|
Carboplatin
|
0.05
|
0.56
|
0.03
|
0.63
|
|
Topotecan
|
0.56
|
0.02
|
0.54
|
0.03
|
|
Bortezomib
|
0.05
|
0.55
|
0.03
|
0.64
|
|
Vinorelbine
|
0.03
|
0.67
|
0.00
|
0.96
|
|
Methotrexate
|
0.60
|
0.01
|
0.57
|
0.02
|
|
Actinomycin D
|
0.20
|
0.23
|
0.14
|
0.32
|
|
Daunorubicin
|
0.13
|
0.34
|
0.07
|
0.48
|
|
Mercaptopurine
|
0.11
|
0.47
|
0.05
|
0.63
|
|
Prednisolone
|
0.48
|
0.04
|
0.42
|
0.06
|
|
Epirubicin
|
0.36
|
0.09
|
0.22
|
0.20
|
|
Mitomycin C
|
0.29
|
0.13
|
0.05
|
0.57
|
- For each individual drug a linear regression analysis was performed comparing survival time and drug efficiency or adjusted drug efficiency. The explanatory value (R2) and p-values are sorted according to the largest gain in explanatory value when adjusting the drug efficiency. Statistically significant departure of the slope from 0 was accepted at p < 0.05 and were found for prednisolone and drug efficiency as well as for topotecan and methotrexate, both for drug efficiency and when adjusting the drug efficiency.
